Berobenatide for Sleep Apnea

This trial aims to test the safety and effectiveness of a new medicine, berobenatide, for people with obstructive sleep apnea (OSA), which causes breathing problems during sleep. Researchers seek to determine if berobenatide can assist those who are overweight or obese and rely on a PAP machine at night. Participants will receive either berobenatide or a placebo (a non-active look-alike) as a monthly injection. Suitable candidates for this trial are adults with moderate to severe OSA, who are overweight or obese, and already using PAP therapy. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

The trial information does not specify whether you need to stop taking your current medications. However, you must continue using your positive airway pressure (PAP) therapy during the study.

Research has shown that berobenatide, a medicine similar to other GLP-1 receptor agonists, is generally well-tolerated. Studies on similar treatments have found they can help with conditions like obstructive sleep apnea (OSA) by improving breathing during sleep. These treatments have been safely used for other conditions, such as type 2 diabetes, indicating their general safety.

Berobenatide is unique because it offers a new approach to treating sleep apnea through subcutaneous injection, which is different from the current standards like CPAP machines, oral appliances, or surgery. Unlike these existing treatments that mainly focus on managing symptoms by keeping airways open during sleep, Berobenatide potentially targets the underlying physiological processes contributing to sleep apnea. Researchers are excited about this treatment because it could simplify management for patients, offering a less invasive and potentially more effective solution with fewer hassles compared to traditional devices or procedures.

Research shows that berobenatide, the investigational treatment in this trial, might help reduce the severity of obstructive sleep apnea (OSA) by aiding weight loss. Studies have found that losing weight can improve sleep apnea symptoms. Specifically, treatments like tirzepatide, known as GLP-1 receptor agonists, have decreased the apnea-hypopnea index (AHI), a measure of breathing interruptions during sleep. These treatments can also enhance other health indicators, such as oxygen levels while sleeping. Early research suggests that berobenatide may have similar effects, offering a hopeful option for people with OSA. Participants in this trial will receive either berobenatide or a placebo to evaluate its effectiveness.³⁵⁶⁷⁸